Marksans Pharma has announced the acquisition of 100% of the share capital of QliniQ B.V., a Dutch pharmaceutical company. This strategic move aims to bolster Marksans’ presence in regulated European markets by leveraging QliniQ’s established sales, marketing, and distribution network. QliniQ reported revenues of €9.35 million and a net profit of €1.01 million for FY2025. The acquisition, valued at €7.5 million, is expected to close by June 15, 2026.
Strategic European Expansion
Marksans Pharma Ltd. has entered into a definitive agreement to acquire 100% of the share capital of QliniQ B.V., a profitable Netherlands-based pharmaceutical company. This acquisition marks a significant step in Marksans’ strategy to expand its presence across regulated European markets and enhance its direct market-access capabilities within the European Union.
About QliniQ B.V.
QliniQ B.V. specializes in niche pharmaceuticals and medical devices, holding established positions in women’s health, dermatology, respiratory care, and other specialty categories. The company boasts strong relationships with wholesalers, pharmacies, hospitals, and insurer-led tender channels in the Netherlands, ensuring sustainable market access and growth. For the financial year ended December 31, 2025, QliniQ reported revenue of €9.35 million and a net profit of €1.01 million. The company has demonstrated robust profitable growth, with revenue increasing at a Compound Annual Growth Rate (CAGR) of approximately 41% between FY2023 and FY2025, while maintaining a debt-free balance sheet.
Deal Rationale and Benefits
The acquisition is expected to provide Marksans with established sales, marketing, and distribution capabilities in the Netherlands, a key European pharmaceutical market. It will grant access to QliniQ’s long-standing relationships with leading wholesalers, pharmacies, hospitals, and health insurers, as well as participation in insurer-led tender channels. This move will bolster Marksans’ presence and support the commercialization of its existing and future product portfolio across regulated European markets.
Financials and Consideration
The total consideration for the acquisition of QliniQ B.V. is €7.5 million, payable in cash. The acquisition is expected to be completed by June 15, 2026, or another mutually agreed-upon date.
About Marksans Pharma Ltd.
Marksans Pharma is a global pharmaceutical company headquartered in Mumbai, engaged in research, manufacturing, marketing, and sale of pharmaceutical formulations. The company operates in multiple international markets, with principal regions including the United States, North America, the United Kingdom, Europe, and Australia & New Zealand. For the financial year ended March 31, 2026, Marksans reported a consolidated total income of approximately ₹3,033 crore and profit after tax of approximately ₹420 crore.
Source: BSE
